Mind Medicine (MindMed) (NASDAQ:MNMD) Stock Rating Upgraded by Roth Capital
Mind Medicine (MindMed) (NASDAQ:MNMD – Get Free Report) was upgraded by analysts at Roth Capital to a “strong-buy” rating in a research note issued to investors on Wednesday, Zacks.com reports. A number of other equities research analysts have also commented on the stock. HC Wainwright reiterated a “buy” rating and set a $35.00 price target […]
More Stories
Pentair plc (NYSE:PNR) Shares Bought by Swedbank AB
Swedbank AB grew its stake in shares of Pentair plc (NYSE:PNR – Free Report) by 17.9% in the third quarter,...
iShares S&P Mid-Cap 400 Value ETF (NYSEARCA:IJJ) Stock Position Trimmed by Wescott Financial Advisory Group LLC
Wescott Financial Advisory Group LLC cut its position in iShares S&P Mid-Cap 400 Value ETF (NYSEARCA:IJJ – Free Report) by...
The PMI Group (OTCMKTS:PPMIQ) and NMI (NASDAQ:NMIH) Head to Head Comparison
NMI (NASDAQ:NMIH – Get Free Report) and The PMI Group (OTCMKTS:PPMIQ – Get Free Report) are both finance companies, but...
Penserra Capital Management LLC Boosts Stake in Innovator U.S. Equity Buffer ETF – May (BATS:BMAY)
Penserra Capital Management LLC lifted its position in Innovator U.S. Equity Buffer ETF – May (BATS:BMAY – Free Report) by...
Pfizer (NYSE:PFE) Stock Acquired Rep. Laurel M. Lee
Representative Laurel M. Lee (R-Florida) recently bought shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on November 21st, the...
Wescott Financial Advisory Group LLC Trims Stock Holdings in Vanguard FTSE Developed Markets ETF (NYSEARCA:VEA)
Wescott Financial Advisory Group LLC decreased its holdings in Vanguard FTSE Developed Markets ETF (NYSEARCA:VEA – Free Report) by 1.2%...